24 May 2013
Keywords: vivus, stock, rising, impotence, challenge, markets, therapy
Article | 09 July 1998
Vivus, which markets the impotence therapy MUSE, an intra-urethralformulation of alprostadil, has seen a dramatic upturn in its share
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
9 July 1998
10 July 1998
8 July 1998
© 2013 thepharmaletter.com